Stocks that pay dividends tend to outperform ones that don't. Consensus price targets for Novo Nordisk suggest the stock can ...

A recent survey highlighted a widespread lack of understanding about the much-publicised GLP-1 weight-loss medications ...

A MUM-OF-TWO who shed almost half her bodyweight using fat jabs has shared the one piece of advice she wish she knew before ...

Eli Lilly's Mounjaro has seen explosive growth since its March launch in India, with sales soaring to Rs 50 crore in three ...

There’s no doubt that GLP-1 drugs like Ozempic have been revolutionary — although the benefits do sometimes come with some ...

WeightWatchers has emerged from bankruptcy after slimming down its debts, as it pledged to combine weight-loss jabs with ...

AFTER ditching Mounjaro for two weeks to go on holiday, a mother has shared what really happens when you stop taking fat jabs ...

The booming uptake of anti-obesity drugs in India is further underscored by rising momentum of Eli Lilly's Mounjaro, which ...

WeightWatchers will announce on Tuesday Dr. Kim Boyd as its chief medical officer, and plans for a new program to help women manage the transition into menopause and beyond, part of its growth ...

Do those on Zepbound have to switch to Wegovy after Caremark drops Zepbound from preferred coverage? What options are there?

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging ...

The incidence of obesity and diabetes is rising in India, the world’s most populous country, which also ranks among the worst ...